InMed Pharmaceuticals (INM) Cash & Current Investments (2020 - 2026)

InMed Pharmaceuticals' Cash & Current Investments history runs 7 years deep, the most recent figure standing at $5.2 million for Q1 2026.

• On a quarterly basis, Cash & Current Investments rose 10.57% year-over-year to $5.2 million in Q1 2026; TTM through Mar 2026 was $5.2 million, a 10.57% increase from a year earlier, with the FY2025 full-year figure at $10.8 million, up 63.07% from the prior year.
• Cash & Current Investments fell to $5.2 million in Q1 2026 per INM's latest filing, from $7.0 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $11.5 million in Q4 2022 and bottomed at $1.3 million in Q3 2024.
• The 5-year median for Cash & Current Investments is $6.6 million (2024), against an average of $6.8 million.
• Across the five-year window, Cash & Current Investments tumbled 88.23% in 2023 and jumped 632.31% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $11.5 million in 2022, then tumbled by 88.23% to $1.4 million in 2023, then soared by 224.37% to $4.4 million in 2024, then soared by 60.54% to $7.0 million in 2025, then declined by 25.57% to $5.2 million in 2026.
• Per Business Quant, the three latest INM Cash & Current Investments figures stand at $5.2 million (Q1 2026), $7.0 million (Q4 2025), and $9.4 million (Q3 2025).